Pharmaceutical Executive January 13, 2025
The Swiss company is focused on developing treatments for respiratory conditions, such as asthma and COPD.
Novo Holdings announced an investment in a $200M Series A launch financing for Swiss company Windward Bio.1 The clinical stage drug development company is developing treatments for immunological diseases with a focus on severe respiratory conditions, such as asthma and COPD.
Windward Bio is in the process of launching Phase II trials for WIN378, a monoclonal antibody targeting the ligand of thymic stromal lymphopoietin. Results from the study are expected to be delivered in 2026, and additional studies for further indications are also in the works.
In a press release, Windward Bio’s founder, CEO, and chairman Luca Santarelli, MD, said, “Our mission in starting...
Today's Sponsors
Today's Sponsor